Clinical implications of urine matrix metalloproteinases assay in patients with chronic glomerulonephritis
- Authors: Li O.A.1, Bobkova I.N.1, Kozlovskaya L.V.1, Lee OA1, Bobkova IN1, Kozlovskaya LV1
-
Affiliations:
- Московская медицинская академия им. И. М. Сеченова
- Issue: Vol 81, No 8 (2009)
- Pages: 10-14
- Section: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/30460
- ID: 30460
Cite item
Full Text
Abstract
Material and methods. ELISA was used for measurement of urinary levels of basic proteolysis system components (MMP-2 and MMP-9), tissue inhibitor TIMP-2 and plasminogen activator inhibitor PAI-1 in four groups of patients. Patients of group 1 (n = 23) had CGN with manifest urinary syndrome (US), of group 2 (n = 26) - CGN with nephritic syndrome (NS), of group 3 (n = 22) - CGN with marked proteinuria (PU) and transient renal failure (RF), group 4 (n = 15) - CGN with high PU and persistent RF.
Results. Patients with enhancing CGN activity (marked US, developing NS, acute nephritic syndrome) had balanced elevation of urinary levels of MMP, TIMP and PAI-1. Development of persistent RF in CGN occurred with imbalance between components of proteolysis system - low urine excretion of MMP and elevation of PAI-1. Urine excretion of MMP and TIMP in patients with progressive CGN directly correlated with 24-h PU and negatively correlated with blood serum creatinine. PAI-1 correlated with severity of RF and fibrosis in renal tissue.
Conclusion. Correlation of changes in urinary excretion of MMP, TIMP and PAI-1 with CGN activity, RF and fibrosis in the kidney confirm the importance of the above urinary tests for estimation of local renal proteolysis and validity of their use for monitoring of extracellulary matrix accumulation (fibrosis) in the kidney and for CGN prognosis.
About the authors
Ol'ga Aleksandrovna Li
Московская медицинская академия им. И. М. Сеченовааспирант, кафедра нефрологии и гемодиализа ФППОВ; Московская медицинская академия им. И. М. Сеченова
Irina Nikolaevna Bobkova
Московская медицинская академия им. И. М. Сеченова
Email: irbo.mma@mail.ru
зав. отделом нефрологии; Московская медицинская академия им. И. М. Сеченова
Lidiya Vladimirovna Kozlovskaya
Московская медицинская академия им. И. М. Сеченовапроф., кафедра терапии и профессиональных заболеваний медико-профилактического факультета; Московская медицинская академия им. И. М. Сеченова
O A Lee
I N Bobkova
L V Kozlovskaya
References
- Nagase H., Woessner J. F. Matrix metalloproteinases. J. Biol. Chem. 1999; 274 (31): 21491-21494.
- Gomes D. E., Alonso D. F., Yoshiji H., Thorgeirsson U. P. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur. J. Cell. Biol. 1997; 74 (2): 111-122.
- Eddy A. A. Plasminogen activator inhibitor-1 and the kidney. Am. J. Physiol. Ren. Physiol. 2002; 283 (2): 209-220.
- Catania J. M., Chen G., Parrish A. R. Role of matrix metalloproteinases in renal pathophysiologies. Am. J. Physiol. Ren. Physiol. 2007; 292: 905-911.
- Sanders J.-S. F., Goor H., Hanemaaijer R. et al. Renal expression of matrix metalloproteinases in human ANCA-associated glomerulonephritis. Nephrol. Dial. Transplant. 2004; 19: 1412-1419.
- Akiyama K., Shikata K., Sugimoto H. et al. Changes in serum concentrations of matrix metalloproteinases, tissue inhibitor of metalloproteinases and type IV collagen in patients with various types of glomerulonephritis. Res. Commun. Mol. Pathol. Pharmacol. 1997; 95: 115-128.
- McMillan J. I., Riordan J. W., Couser W. G. et al. Characterisation of a glomerular epithelial cell matrix metalloproteinase as matrix metalloproteinase-9 with enhanced expression in a model of membranous nephropathy. J. Clin. Invest. 1996; 97:1094-1101.
- Sanders J-S. F., Huitema M., Hanemaaijer R. et al. Urinary matrix metalloproteinases reflect renal damage in anti-neutrophil cytoplasm autoantibody-associated vasculitis. Am. J. Physiol. Ren. Physiol. 2007; 293: 1927-1934.
- Lods N., Ferrari P., Frey F. J. et al. Angiotensin-converting enzyme inhibition but not angiotensin receptor blockade regulates matrix metalloproteinases activity in patients with glomerulonephritis. J. Am. Soc. Nephrol. 2003; 14: 2861-2872.
- Hörstrup J. H., Gehrmann M., Schneider B. et al. Elevation of serum and urine levels of TIMP-1 and tenascin in patients with renal disease. Nephrol. Dial. Transplant. 2002; 17: 1005-1013.
- Мухин Н. А., Козловская Л. В., Бобкова И. Н., Рамеев В. В. Ключевая роль ремоделирования тубулоинтерстиция в прогрессировании хронических заболеваний почек. Apx. пат. 2004; 6: 16-22.
- Козловская Л. В., Бобкова И. Н., Плиева O. K., Чеботарева Н. В. Значение исследования в моче молекулярных медиаторов иммунного воспаления и фиброза в почке при хроническом гломерулонефрите. Тер. аpx. 2004; 9: 84-87.
- Бобкова И. Н., Козловская Л. В., Чеботарева Н. В. Мочевые тесты воспаления и фиброза в оценке прогрессирования хронического гломерулонефрита. Качество жизни 2006; 4: 19-25.
- Бобкова И. Н., Чеботарева Н. В., Козловская Л. В. соавт. Экскреция с мочой моноцитарного хемотаксического протеина-1 и трансформирующего фактора роста-1 как показатель прогрессирования хронического гломерулонефрита. Тер. арх. 2006; 5: 9-14.
- Ng Y. Y., Huang T. P., Yang W. C. Tubular epithelial-myofibroblast transdifferentiation in progressive tubulointerstitial fibrosis in 5/6 nephrectomized rats. Kidney Int. 1998; 54: 864-876.
- Cheng S. Pollock A. S., Mahimkar R. et al. Matrix metalloproteinase 2 and basement membrane integrity: a unifying mechanism for progressive renal injury. FASEB J. 2006; 20: 1898-1900.
- Cheng S., Lovett D. Gelatinase A (MMP-2) is necessary and sufficient for renal tubular cell epithelial-mesenchymal transformation. Am. J. Pathol. 2003; 162: 1937-1949.
- Oda Т., Jung Y. O., Kim H. S. et al. PAI-1 deficiency attenuates the flbrogenic response to ureteral obstruction. Kidney Int. 2001; 60: 587-596.
- Rondeau E., Ochi S., Lacave R. et al. Urokinase synthesis and binding by glomerular epithelial cells in culture. Kidney Int. 1989; 36: 593-600.
![](/img/style/loading.gif)